4D MOLECULAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.99 USD | +0.29% |
|
-8.50% | +3.60% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.
Calendar
17/07/2024
- ASRS Scientific Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
20.99
USD
Average target price
52.3
USD
Spread / Average Target
+149.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.60% | 1.09B | |
| +38.65% | 39.36B | |
| -8.62% | 38.52B | |
| +26.95% | 30.74B | |
| +10.74% | 25.92B | |
| -13.50% | 26.03B | |
| +44.87% | 14.13B | |
| +34.36% | 12.73B | |
| -7.14% | 11.29B | |
| -12.61% | 10.64B |
- Stock Market
- Equities
- FDMT Stock
- News 4D Molecular Therapeutics, Inc.
- 4D Molecular Therapeutics Says US FDA Clears its IND Application for Potential Geographic Atrophy Treatment
